Edition:
India

NeuroMetrix Inc (NURO.OQ)

NURO.OQ on NASDAQ Stock Exchange Capital Market

1.75USD
2:29am IST
Change (% chg)

$0.01 (+0.57%)
Prev Close
$1.74
Open
$1.71
Day's High
$1.79
Day's Low
$1.71
Volume
3,221
Avg. Vol
18,645
52-wk High
$8.96
52-wk Low
$1.45

Chart for

About

NeuroMetrix, Inc. is a healthcare company combining bioelectrical and digital medicine to address chronic health conditions, including chronic pain, sleep disorders and diabetes. The Company is engaged in the sale of medical equipment, and consumables and accessories. It has two principal product lines: Wearable neuro-stimulatio... (more)

Overall

Beta: 0.34
Market Cap(Mil.): $4.00
Shares Outstanding(Mil.): 2.13
Dividend: --
Yield (%): --

Financials

BRIEF-NeuroMetrix CFO reports purchase of 2,500 shares of co's common stock on Oct 23 at $1.77 per share

* NeuroMetrix Inc CFO Thomas​ ‍Higgins reports purchase of 2,500 shares of co's common stock on Oct 23 at $1.77 per share - sec filing Source text (http://bit.ly/2gBQZj2) Further company coverage:

24 Oct 2017

BRIEF-NeuroMetrix files for resale of up to 2.7 mln shares of its stock‍​

* NeuroMetrix files for resale of up to 2.7 million shares of co's common stock issuable upon conversion of shares of series F preferred stock - sec filing‍​ Source text: (http://bit.ly/2un1wUY) Further company coverage:

09 Aug 2017

BRIEF-Neurometrix announces DPNCheck distribution agreement with Fukuda Denshi in Japan

* Neurometrix announces DPNCheck distribution agreement with Fukuda Denshi in Japan Source text for Eikon: Further company coverage:

03 Aug 2017

BRIEF-NeuroMetrix reports Q2 2017 financial results

* NeuroMetrix Inc - loss from operations was $3.4 million in Q2 2017 versus $4.2 million in Q2 2016 Source text for Eikon: Further company coverage:

20 Jul 2017

BRIEF-Neurometrix announces $7.0 mln private placement of preferred stock

* Neurometrix announces $7.0 million private placement of preferred stock

11 Jul 2017

Competitors

  Price Chg
Natus Medical Inc (BABY.OQ) $39.55 0.00

Earnings vs. Estimates